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Abstract
Background: Chemotherapy for cancer is an intense and cyclic treatment associated with number
of side-effects. The present study evaluated the effect of chemotherapy on distress, anxiety and
depression.
Patients and methods: A total of 117 patients were evaluated by using distress inventory for
cancer (DIC2) and hospital anxiety and depression scale (HADS). Majority of the patients were
taking chemotherapy for solid tumors (52; 44.4%).
Results: The mean distress score was 24, 18 (15.38%) were found to have anxiety while 19
(16.23%) had depression. High social status was the only factor found to influence distress while
female gender was the only factor found to influence depression in the present study.
Conclusion: The study highlights high psychological morbidity of cancer patients and influence of
gender on depression. Construct of distress as evaluated by DIC 2 may have a possible overlap
with anxiety.
Background
Treatment of cancer is by three main modalities namely
surgery, radiotherapy and chemotherapy. The hematolog-
ical malignancies and lympho-prolifaretive disorders are
mainly managed by chemotherapy while in solid tumors
chemotherapy is used either as adjuvant or neoadjuvant.
The chemotherapy is an intense and cyclic treatment and
unlike surgery has many side-effects like hair loss, nausea,
vomiting, and diarrhea. Long periods of treatment,
repeated hospitalizations and side-effects of chemother-
apy beside the knowledge of having cancer can all affect
the psyche of these patients. In context of cancer, distress
is defined as extending along a continuum ranging from
common normal feeling of vulnerability, sadness and fear
to problems that can become disabling such as depres-
sion, anxiety and Panic, social isolation and spiritual crisis
[1]. Of these, anxiety is the most commonly seen in cancer
patients. It can occur in four forms i.e. situational anxiety,
disease related anxiety, treatment related anxiety and as an
exacerbation of pre-treatment anxiety disorder [2]. In the
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present study we used distress inventory for cancer version
2 (DIC 2)to measure preclinical distress [3] and hospital
anxiety and depression scale (HADS) to evaluate clinical
case ness for anxiety and depression in patients undergo-
ing chemotherapy to evaluate the effect of chemotherapy
in these patients and other factors that may contribute to
these.
Patients and methods
A total of 117 patients undergoing chemotherapy were
evaluated for distress, anxiety and depression using DIC 2
[3] and Malayalam version of HADS. The results of Malay-
alam translation and validation of HADS has been pub-
lished earlier [4]. After obtaining the written informed
consent two of the co-authors (SGP, DN) carried out the
interviews. It normally took 30–60 minutes for an inter-
view to complete. The interviews were carried out while
the patients were waiting in the day care for their chemo-
therapy. Personal details like age, gender, education, occu-
pation, marital status, religion, and details of spouse and
family were also collected.
Statistical analysis was carried out using one way Anova,
Chi square test and Pearson's product moment correla-
tion.
Tools used
Distress inventory for cancer (DIC 2) is a 33 item tool
which can be administered by an interview or can be self
administered. The tool gives a global distress score beside
subscale scores. The scale is scored on a 5 point Likert
scale, however, the family specific subscale having ques-
tions on spouse and children has additional option of
marking it as not applicable, if the person being inter-
viewed is not married or does not have children. The scor-
ing for the scale and subscale scores is being done as per
the manual for scoring of DIC V2 [3].
Hospital anxiety and depression scale (HADS)
HADS is a 14 item instrument designed to detect the pres-
ence of anxiety and depression. The Malayalam version of
the tool was used. The tool has been translated using
standard formers backward- forward technique and has
been validated [4]. The tool is translated with permission
of nferNelson, UK the copyright owner. A score of 11 or
higher was considered as significant case ness while 8–11
represented mood disturbances.
Permissions
Permission was obtained for Institutional review board
and Ethics committee for the study. Written informed
consent was obtained for all patients being interviewed.
Results
The mean age of the patients were 45.4 ± 15.8 year, there
were 62 (53%) males and 5 (47%) females. At the time of
interview nearly three forth of the patients were married
and over 50% were Hindus. Nearly 45% of the patients
were poor and 31% belonged to upper social class. Of the
117, 52 (44.4%) were taking chemotherapy for solid
tumor while 33 (28%) had lympho-porliferative disease
and 20 (17%) had hematological malignancies. Majority
of the patients 36 (30.8%) had sage III disease. Details of
the patient characteristics are detailed in table 1.
Table 2 describes the distress, anxiety and depression
scores. The mean distress scores were 24.04 ± 9.06 (range
7.14–63.6) while for distress subscales it ranged from
0.0–43.0. The mean anxiety scores were 3.33 ± 3.5 while
for depression it was 4.07 ± 3.24.
Table 3 describes the results of one way Anova. Age above
47 years was found to significantly increase spiritual dis-
tress and activity of daily living while high income and
upper social class patients had less emotional, family spe-
cific and total distress. Hindus and myeloma patients
were found to have significantly high spiritual distress.
Table 1: Patient characteristic
Gender No. Percent (%)
Male 62 53
Female 55 47
Marital status
Married 57 74.4
Single/Widowed 30 25.6
Religion
Hindu 62 53
Christian 33 28.2
Muslim 22 18.8
Social status
Lower 52 44.4
Middle 29 24.8
Upper 36 30.8
Stage of disease
I7 6
II 32 27.4
III 36 30.8
IV 25 21.4
X1 7 1 4 . 5
Type of illness
Solid tumor 52 44.4
Hematological 20 17.1
Lympho-proliferative 33 28.2
Myeloma 12 10.3
Distance traveled
< 150 km 67 57.3
> 150 km 50 42.7World Journal of Surgical Oncology 2006, 4:68 http://www.wjso.com/content/4/1/68
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Table 4 describes the factors influencing anxiety and
depression. Proportion of patients with depression was
slightly higher than anxiety.
Discussion
Chemotherapy given for treatment of cancer kills cells
that are fast dividing, which is hallmark of cancer. In the
process it also kills normal cells that too have a tendency
to divide rapidly like cells in the bone marrow, oral cavity
and mucosal lining of intestine, hair follicles, ova and
sperms. Hence, the side-effects of chemotherapy are
linked to these. The nausea and vomiting at times is so
severe that a subsequent visit to hospital itself may pro-
duce nausea which is termed as "anticipatory nausea".
Like the present study, where a higher proportion of
depression was observed in men compared to women,
gender differences are also observed by other authors,
though in other studies these are seen more in women.
Keller and Henrich (1999) [5] found that women are
more likely than man to engage in illness related behavior
including perceiving and reporting symptoms, utilizing
informal and health care services. It is reported that doc-
tors take symptoms reported by man more seriously while
symptoms reported by women are often interpreted as
psychological ensuing higher frequency of prescriptions
for psychotropic drugs [6]. Despite female patients report-
ing symptoms and higher overall distress due to illness
compared to male patients, general satisfaction with life
however did not differ significantly between genders.
Table 3: Mean scale and subscale scores and Results of one way Anova
Age ED SPD SD MD ADL FSD DIC
<47 Years 26.5 9.5 9 4.3 2.4 12.9 24
>47 Years 24.4 11.0* 9.45 4.4 3.1* 12.2 24
Gender
Male 25.5 10.3 9.5 4.4 2.7 12.8 24.7
Female 25.3 9.7 8.8 4.3 2.9 12.2 23.2
Income
Low 28.3 9.7 9.2 4.3 3.2 13.8 26.9
Middle 24.1 11.0 9.2 4.6 2.6 12.6 24.1
High 22.2** 9.6 9.3 4.3 2.3 10.7*+ 19.7**+
Religion
Hindu 25.4 11.5 9.5 4.4 2.9 12.2 25.4
Non-Hindu 25.4 8.3** 8.8 4.3 2.7 12.8 22.4
Marital Status
Married 26 10.2 9.4 4.3 2.9 __≠ 24.7
Single/Widowed 23.6 9.5 8.7 4.4 2.5 __ 22.0
Type of Cancer
Hematological 26.6 9.1 8.4 4.4 2.7 12.5 23.8
Lympho-proliferative 25.9 8.5 9.5 4.2 2.7 11.6 22.8
Solid 24.4 10.9 9.2 4.4 2.7 13.1 24.3
Myeloma 26.1 12.0*# 9.5 4.5 3.2 12.2 26.3
Stage of Disease
Stage I 24.4 8.7 10.2 4.0 2.1 13.5 22.8
Stage II 23.3 9.3 9.3 4.4 2.5 11.7 21.4
Stage III 24.8 11.4 9.4 4.3 3.0 11.4 24.1
Stage IV 28.4 9.8 9.8 4.4 3.1 13.5 268
Distance traveled
> 150 km 25.4 10 9.2 4.3 2.9 12.0 23.6
> 150 km 25.5 10.1 9.2 4.4 2.6 13.2 24.5
+ low with high * Significance ≤ 0.05 ** Highly significance ≤ 0.001
≠ no comparison was made as score for single/widowed group was zero for this subscale.
# Lympho-prolifrative with solid tumors and myeloma.
Table 2: The distress, anxiety and depression scores
Distress inventory V2 Mean SD Median Min Max
Emotional distress 25.4 7.56 25 10 43
Spiritual distress 10.0 3.64 9 5 25
Social distress 9.23 2.79 9 6 19
Medical distress 4.39 0.78 4 4 8
Activity of daily living 2.8 1.8 2 1 5
Family specific distress 9.68 6.11 11 0 23
Total distress (DIC2) 24 9.06 22.7 7.14 63.64
HADS
Anxiety 3.33 3.5 2 0 14
Depression 4.07 3.24 3 0 16World Journal of Surgical Oncology 2006, 4:68 http://www.wjso.com/content/4/1/68
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Symptom occurrence, their intensity and symptom dis-
tress has been studied from time of admission to dis-
charge in patients undergoing high dose chemotherapy
and stem cell transplant [7]. The results suggested that
symptom occurrence followed a curve where highest fre-
quency of symptoms was noted from the day of transplant
to the end of protective care period. These included tired-
ness, loss of appetite, dryness of mouth, nausea and sleep
disturbances [7] most importantly patients reported to
have anxiety at the beginning were found to have higher
anxiety at the end. No such comparison could be made in
present study due to its cross-sectional design. Trask et al
(2003) [8], too showed that 30–50% of the subjects show
moderate to high level of distress before the start of the
treatment. Dose intense adjuvant chemotherapy regimens
showed higher although transient psychological distress
in early breast cancers in a study [9]. Another study found
significantly higher amount of anxiety in patients receiv-
ing chemotherapy [10]. In the present study however,
there was no other group to compare proportion of
patients with anxiety and depression. Granisetron an
antiemetic has also been found to be less effective in
patients with manifest anxiety [11]. Effect of age has been
evaluated and older patients and men had been found to
have less anxiety and depression [12], we however failed
to find any such relation in our study. Symptom anxiety
and symptom experience in patients undergoing chemo-
therapy has been examined and significant association
were found with psychological symptoms but not for vis-
ible symptoms [13], however in the present study we did
not observe any relations with symptoms.
Cancer related depression is a pathological affective
response to loss of normality and one's personal world as
a result of cancer diagnosis, treatment or impending com-
plications. Similar to Grief, depression presents with
Table 4: Results of factors influencing anxiety and depression.
Age Anxiety χ2 pD e p r e s s i o n χ2 p
+- + -
< 47 8 49 11 46
0.01 0.8 0.38 0.53
> 47 10 50 8 52
Gender
Male 10 52 14 48
0.05 0.81 3.8 0.04*
Female 8 47 5 50
Income
Low 12 40 11 41
Middle 2 27 4.4 0.10 3 26 1.8 P = 0.40
High 4 32 5 31
Religion
Hindu 11 51 9 53
0.5 0.45 0.2 0.59
Non Hindu 7 48 10 45
Marital status
Married 13 74 16 71
0.05 0.82 1.1 0.28
Single/widow 5 25 3 27
Disease type
Hematological 3 17 3 17
Lympho-proliferative 3 30 4 29
2.79 0.42 1.2 0.73
Solid tumor 11 41 11 41
Myeloma 1 11 2 11
Stage
Stage I 1 6 1 6
Stage II 4 28 4 28
0.6 0.89 1.6 0.65
Stage III 7 29 5 31
Stage IV 4 21 6 19
Distance
< 150 11 56 10 57
0.12 0.17 0.19 0.65
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symptoms of sadness, fearfulness feeling of panic and
yearning for lost objects [14]. Depression is suspected
when symptoms of sadness persist and are accompanied
by increasing dysfunction, feeling of worthlessness, low-
ered self-esteem, suicidal preoccupation or inability to
anticipate anything with pleasure [15]. Miranda et al.,
(2002) [16] evaluated depression in breast and cervix can-
cer patients undergoing neoadjuvant chemotherapy and
found no difference in proportion of depressed however,
the number of depression patients increased after chemo-
therapy for breast cancer which is reduced for uterine cer-
vix cancer [16]. The patients who responded to treatment
were less depressed. Though the number of patients with
depression in the present study was low, still the need for
intervention to improve psychological morbidity cannot
be ignored. Distress appears to be present in early part of
continuum and may have possible overlap with anxiety.
Further studies with higher sample size are needed to fur-
ther elucidate this relationship.
Conclusion
The study highlights high psychological morbidity of can-
cer patients and influence of gender on depression. Con-
struct of distress as evaluated by DIC 2 may have a
possible overlap with anxiety
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